Part I: Why Biologic Patents Are a Different Animal A biologic patent application is not a harder version of a […]

A deep-dive reference for IP teams, R&D leads, patent counsel, and portfolio managers navigating combination therapy exclusivity Section 1: Executive

The Affordability Paradox: Why Thin Margins Are a Systemic Risk Generic drugs filled 91% of all U.S. prescriptions in 2022,

Part I: Market Architecture and the Valuation Problem Why the Headlines Are Misleading The Latin American generic drug market will

Section 1: What Biosimilar Cost-Effectiveness Actually Measures The Misread Metric Most coverage of biosimilars collapses cost-effectiveness into a single question:

Somewhere in a regulatory affairs department right now, a development team is arguing about whether to run a comparative clinical

There is a certain type of pharmaceutical executive who still thinks of patent searching as something lawyers do—a back-office function

Generic drug approval is, at its core, a race with rules. The company that reads the rules fastest and most

Biosimilar-to-Biosimilar Switching: The Complete IP, Clinical, and Market Playbook For pharma IP teams, portfolio managers, R&D leads, and institutional investors